```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:36:19 ON 25 JAN 2007

=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY     SESSION
FULL ESTIMATED COST                                         0.42        0.42

FILE 'CAPLUS' ENTERED AT 10:37:13 ON 25 JAN 2007

=> s helm j s/au and walker s/au and py=2003
             0 HELM J S/AU
           213 WALKER S/AU
       1261591 PY=2003
L1           0 HELM J S/AU AND WALKER S/AU AND PY=2003

=> s helm j/au and walker s/au and py=2003
            28 HELM J/AU
           213 WALKER S/AU
       1261591 PY=2003
L2           0 HELM J/AU AND WALKER S/AU AND PY=2003

=> s walker s/au and py=2003
           213 WALKER S/AU
       1261591 PY=2003
L3           6 WALKER S/AU AND PY=2003

=> s generizable and l3
             0 GENERIZABLE
L4           0 GENERIZABLE AND L3

=> d scan l3

L3    6 ANSWERS   CAPLUS  COPYRIGHT 2007 ACS on STN
CC   37-5 (Plastics Manufacture and Processing)
TI   Effect of material properties on the mechanical and thermal performance of
     metallocene catalysed LLDPEs
ST   metallocene catalyzed LLDPE thermal mech property
IT   Crystallinity
     Density
     Elongation at break
     Flexural modulus
     Impact strength
     Mechanical loss
     Modulus (stress-strain)
     Storage modulus
        (effect of material properties on mech. and thermal performance of
        metallocene catalyzed LLDPEs)
IT   Linear low density polyethylenes
     RL: PRP (Properties)
        (effect of material properties on mech. and thermal performance of
        metallocene catalyzed LLDPEs)
IT   Stress, mechanical
        (yield; effect of material properties on mech. and thermal performance
        of metallocene catalyzed LLDPEs)
IT   25213-02-9, Ethylene-1-hexene copolymer
     RL: PRP (Properties)
        (Elenac 18QFA, Exxon LL 3002, Mitsui SP 250, Elenac 18PFAX, Elenac
        18TFA, Elenac 18RFA, Phillips 143SA, Phillips D 350; effect of material
```

properties on mech. and thermal performance of metallocene catalyzed LLDPEs)
IT 800392-61-4, Ethylene-1-octene copolymer
RL: PRP (Properties)
(Elite 5400, Elite 5200, Elite 5100, Elite 5110, Nova 21837, Nova 18909, Nova 21683; effect of material properties on mech. and thermal performance of metallocene catalyzed LLDPEs)
IT 25087-34-7, 1-Butene-ethylene copolymer
RL: PRP (Properties)
(Exxon MMA 043; effect of material properties on mech. and thermal performance of metallocene catalyzed LLDPEs)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 6 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 17-10 (Food and Feed Chemistry)
TI The use of fruit pulps to explore flavour in kiwifruit
ST Actinidia flavor sugar acid; kiwifruit flavor sugar acid
IT Acidity
Actinidia chinensis
Flavor
Sweetness
(sugar and acid effect on flavor in kiwifruit)
IT Carbohydrates, biological studies
Carboxylic acids, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(sugar and acid effect on flavor in kiwifruit)
IT 50-81-7, Vitamin C, biological studies 50-99-7, D-Glucose, biological studies 57-48-7, D-Fructose, biological studies 57-50-1, Sucrose, biological studies 77-92-9, Citric acid, biological studies 77-95-2, Quinic acid 87-89-8, myo-Inositol 6915-15-7, Malic acid
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(sugar and acid effect on flavor in kiwifruit)

L3 6 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-4 (Mammalian Hormones)
TI Estrogen and LH dynamics during the follicular phase of the estrous cycle in the Asian elephant
ST estrogen LH follicular phase elephant
IT Endocrine system
(anterior pituitary-ovary; estrogen and LH dynamics during follicular phase in Asian elephants)
IT Elephas maximus
(estrogen and LH dynamics during follicular phase in Asian elephants)
IT Estrogens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(estrogen and LH dynamics during follicular phase in Asian elephants)
IT Ovarian cycle
(follicular phase; estrogen and LH dynamics during follicular phase in Asian elephants)
IT Ovarian cycle
(luteal phase; steroid and LH dynamics during ovarian cycle in Asian elephants)
IT Progestogens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(steroid and LH dynamics during ovarian cycle in Asian elephants)
IT Urine
(urinary estrogen and serum LH dynamics during follicular phase in Asian elephants)
IT 9002-67-9, LH

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(estrogen and LH dynamics during follicular phase in Asian elephants)

L3 6 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 73-5 (Optical, Electron, and Mass Spectroscopy and Other Related Properties)
TI Photoluminescence emission and Raman scattering polarization in birefringent organic microcavities in the strong coupling regime
ST luminescence Raman scattering birefringence microcavities polariton J aggregate
IT Cavity resonators
(micro; photoluminescence emission and Raman scattering polarization in birefringent organic microcavities in strong coupling regime)
IT Birefringence
J-aggregates
Luminescence
Molecular vibration
Polariton
Raman spectra
(photoluminescence emission and Raman scattering polarization in birefringent organic microcavities in strong coupling regime)

L3 6 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 63-5 (Pharmaceuticals)
TI Distribution of technetium-99m-labelled QVAR delivered using an Autohaler device in children
ST QVAR hydrofluoroalkane aerosol inhaler asthma lung gastrointestinal tract infant; beclomethasone dipropionate inhalant oropharynx lung deposition infant age
IT Drug delivery systems
(aerosols, inhalants; distribution of 99mTc-labeled QVAR delivered by Autohaler device in asthmatic children)
IT Development, mammalian postnatal
(child; distribution of 99mTc-labeled QVAR delivered by Autohaler device in asthmatic children)
IT Asthma
Breathing (animal)
Digestive tract
Human
Lung
Particle size
Particle size distribution
Propellants (sprays and foams)
(distribution of 99mTc-labeled QVAR delivered by Autohaler device in asthmatic children)
IT Aging, animal
(distribution of 99mTc-labeled QVAR delivered by Autohaler device in asthmatic children in relation to age)
IT Alkanes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fluoro; distribution of 99mTc-labeled QVAR delivered by Autohaler device in asthmatic children)
IT Medical goods
(inhalers, Autohaler; distribution of 99mTc-labeled QVAR delivered by Autohaler device in asthmatic children)
IT Pharynx
(oropharynx; distribution of 99mTc-labeled QVAR delivered by Autohaler device in asthmatic children)
IT 5534-09-8, QVAR 18559-94-9, Salbutamol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(distribution of 99mTc-labeled QVAR delivered by Autohaler device in asthmatic children)

L3 6 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 37-5 (Plastics Manufacture and Processing)
Section cross-reference(s): 38
TI The influence of mould temperature and polymer structure on the mechanical and thermal properties of metallocene catalysed LLDPEs
ST mold temp LLDPE structure mech thermal property
IT Crystallinity
Elongation at break
Impact strength
Mechanical loss
Modulus (stress-strain)
Viscosity
(effect of mold temperature and polymer structure on mech. and thermal properties of metallocene catalyzed LLDPEs)
IT Linear low density polyethylenes
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
(effect of mold temperature and polymer structure on mech. and thermal properties of metallocene catalyzed LLDPEs)
IT Molding of plastics and rubbers
(injection; effect of mold temperature and polymer structure on mech. and thermal properties of metallocene catalyzed LLDPEs)
IT 26221-73-8, Elite 5100
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
(Elite 5100, Elite 5200, Elite 5400; effect of mold temperature and polymer structure on mech. and thermal properties of metallocene catalyzed LLDPEs)
IT 26221-73-8, Elite 5110
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
(Elite 5110; effect of mold temperature and polymer structure on mech. and thermal properties of metallocene catalyzed LLDPEs)
IT 74-85-1D, Ethene, polymers with α-olefins, polymers with α-olefins 25213-02-9, Ethylene-1-hexene copolymer
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
(effect of mold temperature and polymer structure on mech. and thermal properties of metallocene catalyzed LLDPEs)

ALL ANSWERS HAVE BEEN SCANNED.

=> s walker s/au and glycosyltransferase
213 WALKER S/AU
4424 GLYCOSYLTRANSFERASE
2611 GLYCOSYLTRANSFERASES
5554 GLYCOSYLTRANSFERASE (GLYCOSYLTRANSFERASE OR GLYCOSYLTRANSFERASES)
L5 1 WALKER S/AU AND GLYCOSYLTRANSFERASE

=> d

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:621575 CAPLUS Full-text
DN 135:223201
TI E. coli MurG: a paradigm for a superfamily of glycosyltransferases

```
AU   Ha, S.; Gross, B.; Walker, S.
CS   Chemistry Department, Princeton University, Princeton, NJ, 08544, USA
SO   Current Drug Targets: Infectious Disorders (2001), 1(2), 201-213
     CODEN: CDTIAS; ISSN: 1568-0053
PB   Bentham Science Publishers Ltd.
DT   Journal; General Review
LA   English
RE.CNT  73    THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s walker/au and glycosyltransferase
             5 WALKER/AU
          4424 GLYCOSYLTRANSFERASE
          2611 GLYCOSYLTRANSFERASES
          5554 GLYCOSYLTRANSFERASE
                 (GLYCOSYLTRANSFERASE OR GLYCOSYLTRANSFERASES)
L6           0 WALKER/AU AND GLYCOSYLTRANSFERASE

=> s walker ?/au and glycosyltransferase
         35086 WALKER ?/AU
          4424 GLYCOSYLTRANSFERASE
          2611 GLYCOSYLTRANSFERASES
          5554 GLYCOSYLTRANSFERASE
                 (GLYCOSYLTRANSFERASE OR GLYCOSYLTRANSFERASES)
L7          31 WALKER ?/AU AND GLYCOSYLTRANSFERASE

=> s l7 and py=2003
       1261591 PY=2003
L8           4 L7 AND PY=2003

=> d scan

L8    4 ANSWERS   CAPLUS  COPYRIGHT 2007 ACS on STN
CC   1-5 (Pharmacology)
     Section cross-reference(s): 7, 10
TI   Identification of Active-Site Inhibitors of MurG Using a Generalizable,
     High-Throughput Glycosyltransferase Screen
ST   MurG glycosyltransferase inhibitor identification high
     throughput screen
IT   Antibacterial agents
     Combinatorial library
     Drug screening
     High throughput screening
        (identification of active-site inhibitors of MurG using a generalizable
        high-throughput glycosyltransferase screen in relation to
        antibacterial activity)
IT   Enzyme functional sites
        (inhibitor-binding; identification of active-site inhibitors of MurG
        using a generalizable high-throughput glycosyltransferase
        screen in relation to antibacterial activity)
IT   Enzyme kinetics
        (of inhibition; identification of active-site inhibitors of MurG using
        a generalizable high-throughput glycosyltransferase screen in
        relation to antibacterial activity)
IT   608143-47-1
     RL: BUU (Biological use, unclassified); PAC (Pharmacological activity);
     BIOL (Biological study); USES (Uses)
        (displacement ligand; identification of active-site inhibitors of MurG
        using a generalizable high-throughput glycosyltransferase
```

```
        screen in relation to antibacterial activity)
IT   60976-26-3, MurG glycosyltransferase
     RL: BSU (Biological study, unclassified); BUU (Biological use,
     unclassified); BIOL (Biological study); USES (Uses)
        (identification of active-site inhibitors of MurG using a generalizable
        high-throughput glycosyltransferase screen in relation to
        antibacterial activity)
IT   312501-65-8
     RL: PAC (Pharmacological activity); BIOL (Biological study)
        (identification of active-site inhibitors of MurG using a generalizable
        high-throughput glycosyltransferase screen in relation to
        antibacterial activity)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):file stnguide
'FILE STNGUIDE' IS NOT VALID HERE

To display more answers, enter the number of answers you would like to
see.  To end the display, enter "NONE", "N", "0", or "END".
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0


=> FIL REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.06      38.99

FILE 'REGISTRY' ENTERED AT 10:44:26 ON 25 JAN 2007

=> S 608143-47-1/RN

L9            1 608143-47-1/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L9 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.55 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L9   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   608143-47-1  REGISTRY
CN   Uridine 5'-(trihydrogen diphosphate), P'-[2-deoxy-2-[[[[(3',6'-dihydroxy-3-
     oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-
     yl)carbonyl]amino]acetyl]amino]-α-D-glucopyranosyl] ester (9CI)  (CA
     INDEX NAME)
FS   STEREOSEARCH
MF   C38 H38 N4 O23 P2
SR   CA
LC   STN Files:   CA, CAPLUS, USPATFULL
DT.CA  CAplus document type:  Journal; Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); USES
       (Uses)
RL.NP  Roles from non-patents:  BIOL (Biological study); USES (Uses)

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> file caplus uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.40	41.39

FILE 'CAPLUS' ENTERED AT 10:45:02 ON 25 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 10:45:02 ON 25 JAN 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l9
L10 4 L9

=> dup rem l10
PROCESSING COMPLETED FOR L10
L11 3 DUP REM L10 (1 DUPLICATE REMOVED)
ANSWERS '1-3' FROM FILE CAPLUS

=> d bib abs 1-3

L11 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1

AN 2005:572457 CAPLUS Full-text
DN 143:90985
TI Identification of active-site inhibitors of glycosyltransferases using a generalizable high-throughput screen
IN Kahne, Suzanne Walker; Kahne, Daniel
PA USA
SO U.S. Pat. Appl. Publ., 26 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005142629	A1	20050630	US 2003-748335	20031230
PRAI US 2003-748335		20031230		

OS MARPAT 143:90985
AB A method is described for identifying a compound that modulates the ability of a glycosyltransferase to bind a substrate, comprising combining a glycosyltransferase, a labeled substrate, and a compound, in a reaction vessel, under conditions known to be suitable for the glycosyltransferase to bind the labeled substrate, measuring an amount of labeled substrate bound to the glycosyltransferase, and comparing the amount to a standardized amount to identify a relative increase or decrease in substrate bound glycosyltransferase, thereby identifying a compound that modulates the ability of the glycosyltransferase to bind the substrate. A composition comprising an effective amount of a compound that inhibits the ability of a glycosyltransferase to bind a substrate, in a pharmaceutically acceptable carrier, is also provided. The invention further provides methods for controlling the growth of bacteria using the compds. of the invention. Compds. of the invention include e.g. 5-(4-tert-butylbenzylidene)-3-(4-methylpiperidin-1-ylmethyl)-2-thioxothiazolidin-4-one. Preparation of a fluoresceinated UDP-N-acetylglucosamine analog is included.

L11 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1039666 CAPLUS Full-text
DN 144:18650
TI Discovery of O-GlcNAc Transferase Inhibitors
AU Gross, Benjamin J.; Kraybill, Brian C.; Walker, Suzanne
CS Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA, 02115, USA
SO Journal of the American Chemical Society (2005), 127(42), 14588-14589
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
OS CASREACT 144:18650
AB O-GlcNAcylation of serine and threonine residues is a dynamic and essential post-translational modification involved in signaling pathways in eukaryotes. Studies of O-GlcNAcylation would be aided by small-mol. inhibitors of O-GlcNAc transferase (OGT), the sole enzyme known to mediate this modification, but discovery of such mols. has been hampered by poor expression of cloned OGT and lack of suitable high-throughput screens. This communication describes the expression of large amts. of the catalytic domain of OGT and the implementation of a fluorescence-based substrate analog displacement assay that has led to the discovery of a set of OGT inhibitors. This work lays the foundation for both structural and functional anal. of the catalytic domain of OGT.
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:652522 CAPLUS Full-text
DN 139:285735
TI Identification of Active-Site Inhibitors of MurG Using a Generalizable, High-Throughput Glycosyltransferase Screen
AU Helm, Jeremiah S.; Hu, Yanan; Chen, Lan; Gross, Ben; Walker, Suzanne
CS Department of Chemistry, Princeton University, Princeton, NJ, 08544, USA
SO Journal of the American Chemical Society (2003), 125(37), 11168-11169
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
AB MurG is a glycosyltransferase involved in the biosynthesis of bacterial peptidoglycan. It is a potentially important antibiotic target, but no inhibitors of the enzyme have been reported. In general, inhibitors of glycosyltransferases have been difficult to design. Furthermore, no glycosyltransferase inhibitors have been identified through high-throughput screening, perhaps because appropriate screens for glycosyltransferase inhibition have not been developed. In this manuscript, the authors describe the development of a high-throughput screen for MurG that was used to screen a 50 000 compound library for inhibitors. The screen, which can be generalized to other glycosyltransferases, led to the identification of a family of active-site directed MurG inhibitors. The family of inhibitors contains a five-membered heterocyclic core that appears to function as a diphosphate mimic with respect to the presentation of substituents. The authors discuss the implications of this result and the utility of the screen for identifying inhibitors of other glycosyltransferases.
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.45	51.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

FILE 'STNGUIDE' ENTERED AT 10:45:48 ON 25 JAN 2007

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan 19, 2007 (20070119/UP).

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	51.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.34

STN INTERNATIONAL LOGOFF AT 10:46:26 ON 25 JAN 2007